![Sar-[D-Phe8]-des-Arg9-Bradykinin](https://file.medchemexpress.com/product_pic/hy-103291.gif "Click to View Sar-[D-Phe8]-des-Arg9-Bradykinin Product Detail")
![Lys-[Des-Arg9]Bradykinin TFA](https://file.medchemexpress.com/product_pic/hy-103295a.gif "Click to View Lys-[Des-Arg9]Bradykinin TFA Product Detail")
![Lys-[Des-Arg9]Bradykinin](https://file.medchemexpress.com/product_pic/hy-103295.gif "Click to View Lys-[Des-Arg9]Bradykinin Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
Kinin B1 receptor
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "Kinin B1 receptor" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
Cat. No.: HY-W704574
CAS No.: 77102-28-4
Research Areas:
Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats .
Target:
Research Areas:
Target:
Research Areas:
Cat. No.: HY-103295
CAS No.: 71800-36-7
Target:
Research Areas:
Cat. No.: HY-100827
CAS No.: 633698-99-4
Synonyms: LF22-0542
Target:
Research Areas:
Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model .
Cat. No.: HY-15041
CAS No.: 312722-60-4
Target:
Research Areas:
NVP-SAA164 is an orally active nonpeptide kinin B1 receptor antagonist. NVP-SAA164 reverses CFA (Complete Freund's adjuvant) (HY-153808)-induced mechanical hyperalgesia and desArg10KD-induced hyperalgesia in hB1-KI mice, and is inactive in a model of inflammatory pain in wild-type mice .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
